SPOKANE, Wash. and VANCOUVER, British Columbia, Oct. 2, 2019 /PRNewswire/ -- Today, U.S.-based MEDITECH partner Engage and Vancouver,

SAN JOSE, Calif., Oct. 2, 2019 /PRNewswire/ -- Outset Medical, a commercial-stage company delivering first-of-its-kind technology into the growing global dialysis market, today announced the U.S. Department of Health and Human Services (HHS) awarded a contract for the use of the Tablo™ Hemodialysis Systems to serve dialysis patients in communities hit by natur

KANSAS CITY, Mo., Oct. 2, 2019 /PRNewswire/ -- Medicare Shared Savings Program performance results released this week show Caravan Health accountable care organizations (ACOs) are leaders in

NORTH CHICAGO, Ill., Oct. 2, 2019 /PRNewswire/ -- In accordance with Rule 2.10 of the Irish Takeover Panel Act, 1997, Takeover Rules 2013, AbbVie Inc. confirms that as of September 30, 2019 its issued share capital, excluding treasury shares, is comprised of 1,478,782,106 shares of common stock with a par value of $0.0

HUDDINGE, Sweden, Oct. 2, 2019 /PRNewswire/ -- On  September 17th 2019 Karolinska University Hospital became the first hospital in the Nordic region to use laser ablation technique in the treatment of a patient with a brain tumor. The patient treated was discharged the day after surgery with only a single stitch covering the dril

LINKÖPING, Sweden, Oct. 2, 2019 /PRNewswire/ --  International medical imaging IT and cybersecurity company Sectra (STO: SECT B) is extending its pre-operative orthopae

EAST HANOVER, N.J., Oct. 2, 2019 /PRNewswire/ -- Novartis, a leader in rheumatology and immuno-dermatology, today announced additional positive data from the PREVENT trial, evaluating the efficacy and safety of Cosentyx® (secukinumab) in patients with non-radiographic axial spondyloarthritis (nr-axSpA). The ongoing Phase III trial met its primary endp

BERGEN, Norway, Oct. 2, 2019 /PRNewswire/ -- BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for multiple cancer indications, is pleased to announce it has been accepted for an oral presentation at the Society for Immunotherapy of Cancer (SITC)'s 34th Annual Meeting, which is being held from

ADELAIDE, Australia, Oct. 2, 2019 Mayne Pharma Group Limited (Mayne Pharma or Company) (ASX: MYX) has signed a 20‑year exclusive supply and license agreement with Mithra Pharmaceuticals, SA (Mithra) to commercialise a novel oral contraceptive comprising Estetrol (E4), and drospirenone, (E4/DRSP) in

SAN JOSE, Calif., Oct. 1, 2019 /PRNewswire/ -- Meditrina, Inc., a women's healthcare company and the developer of the Aveta™ System for the treatment of various intrauterine pathologies such as polyps and fibroids, announced today that it has completed a $13 million equity financing. The financing was led by ShangBay Capital LLC a